Ward: Tech Stocks

HAYA Therapeutics announced that the first cohort has been fully enrolled and dosed in its Phase 1 clinical trial of HTX-001, an investigational antisense oligonucleotide that targets the WISPER long non-coding RNA, according to the company. The molecule is designed to downregulate WISPER in cardiac…

Happy 85% Chaos 20% Sad 5% Well 70% Anger 10% Fear 5% Surprise 30%

0

Celestica: The Quiet Backbone Of The AI Hardware Revolution

Happy 30% Chaos 20% Sad 10% Well 20% Anger 10% Fear 5% Surprise 20%

0

TTM Technologies: Negative On Valuation, Positive On Fundamentals

Happy 75% Chaos 10% Sad 5% Well 20% Anger 10% Fear 5% Surprise 20%

0

Mirion Technologies: Gradually Becoming More Attractive

Happy 85% Chaos 20% Sad 5% Well 60% Anger 10% Fear 5% Surprise 30%

0

Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript

Happy 85% Chaos 15% Sad 0% Well 0% Anger 0% Fear 0% Surprise 50%

0

My Oh My, What A Month Of May

Happy 75% Chaos 20% Sad 5% Well 80% Anger 10% Fear 5% Surprise 30%

0

Amazon: The Stock Is Missing The AI Wave, But The Business Isn't

Happy 85% Chaos 20% Sad 5% Well 30% Anger 10% Fear 5% Surprise 70%

0

Optical And IP Momentum To Push Nokia Network Revenues Up 14% In 2026

Happy 30% Chaos 20% Sad 40% Well 10% Anger 60% Fear 40% Surprise 10%

0

KLA Corporation: Another Victim Of Semiconductor Euphoria

Happy 70% Chaos 10% Sad 5% Well 20% Anger 5% Fear 5% Surprise 30%

0

SpaceX sets aside up to 5% of shares in IPO for certain employees and friends

In an updated IPO prospectus, SpaceX said that up to 5% of stock being offered by the company in the offering will be available in a direct share program.

Happy 50% Chaos 30% Sad 10% Well 20% Anger 10% Fear 20% Surprise 50%

0

Anthropic confidentially files IPO prospectus with SEC, prepping Wall Street for landmark AI deal

Anthropic said it confidentially filed its IPO prospectus with the SEC, setting up a potentially historic share sale for investors ready to jump into AI.